FILE:CELG/CELG-8K-20061207190716.txt.gz
EVENTS:	Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers	Financial Statements and Exhibits
TEXT:
ITEM: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM: Financial Statements and Exhibits
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 6, 2006 CELGENE CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-16132 22-2711928 - -------------------------------------------------------------------------------- (State or other jurisdiction of (Commission File Number) (IRS Employer incorporation) Identification No.) 86 Morris Avenue, Summit, New Jersey 07901 - -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (908) 673-9000 ------------------------------------------------------------ (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): [_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. APPOINTMENT OF CHIEF FINANCIAL OFFICER On December 7, 2006, Celgene Corporation announced the appointment of David W. Gryska as Chief Financial Officer. Mr. Gryska will lead the worldwide finance organization, which includes accounting and reporting, strategic planning and analysis, treasury, tax, audit, and corporate communications. In connection with this appointment, Mr. Gryska will receive an annual base salary of $450,000; will be eligible to participate in the Management Incentive Plan with an incentive target equal to 50% of his annual base salary and maximum award equal to 200% of the target award; is expected to participate in the 2007 - 2009 Long Term Incentive Plan, or LTIP, with a payout targeted at 50% of his annual base salary and a maximum potential payout of 100% of his annual base salary contingent upon approval of the plan by the Compensation Committee. Payout under the 2007 - 2009 LTIP Plan is in 2010 contingent upon achievement of established goals. Mr. Gryska has also been granted the option to purchase 25,000 shares of Celgene Corporation common stock and will be granted an additional 25,000 options pursuant to the 1998 Stock Incentive Plan on March 6, 2007, June 6, 2007 and September 6, 2007. Attached hereto and incorporated herein by reference as Exhibit 99.1 is the Press Release announcing the appointment. ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. Exhibits 99.1 - Press Release dated December 7, 2006 announcing the appointment of David W. Gryska as Chief Financial Officer. SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELGENE CORPORATION Date: December 7, 2006 By: /s/ Robert J. Hugin ---------------------------------- Name: Robert J. Hugin Title: President and Chief Operating Officer
EXHIBIT INDEX EXHIBIT NO. DESCRIPTION - ----------- ----------- 99.1 Press release dated December 7, 2006 announcing the appointment of David W. Gryska as Chief Financial Officer.

Exhibit 99.1 Contact: Robert J. Hugin Brian P. Gill President & COO Senior Director PR/IR Celgene Corporation Celgene Corporation (908) 673-9102 (908) 673-9530 Celgene Names David W. Gryska Chief Financial Officer SUMMIT, NJ - (DECEMBER 7, 2006) - Celgene Corporation (NASDAQ: CELG) announced that David W. Gryska has joined the company as Chief Financial Officer. Mr. Gryska brings with him extensive business experience as having served as a Chief Financial Officer of public companies for more than ten years, most recently at SCIOS Inc., a biopharmaceutical company that was acquired by Johnson & Johnson. Earlier in his career, Mr. Gryska spent eleven years at Ernst & Young where he rose to partner and was responsible for managing audit and consulting services for private and public held biotechnology and healthcare companies. "We are very pleased to have David join our senior management team at Celgene during a period of such rapid growth where his business building skills and financial experience will contribute broadly to our finance, operations and global business strategy," said Sol J. Barer, Ph.D., Chief Executive Officer at Celgene Corporation. As CFO, Mr. Gryska will lead the worldwide finance organization and will have responsibility for accounting and reporting, strategic planning and analysis, treasury, tax, audit, and corporate communications. Most recently, Mr. Gryska was a principal at Strategic Consulting Group where he was responsible for investing and providing strategic consulting to earlier-stage biotechnology companies. From 1998 to 2004, Mr. Gryska served for six years as Senior Vice President and Chief Financial Officer at SCIOS, Inc., where he was responsible for all finance functions, manufacturing, business development and corporate communications. From 1993 to 1998, Mr. Gryska served as the Chief Financial Officer of Cardiac Pathways, a medical-device company that was acquired by Boston Scientific. Mr. Gryska also serves as a member of the board of directors of Seattle Genetics, CoTherix Inc., and Phenomix. He will report to Sol J. Barer, Ph.D, Chief Executive Officer of Celgene Corporation. ABOUT CELGENE Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com. THIS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS WHICH ARE SUBJECT TO KNOWN AND UNKNOWN RISKS, DELAYS, UNCERTAINTIES AND OTHER FACTORS NOT UNDER THE COMPANY'S CONTROL, WHICH MAY CAUSE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE COMPANY TO BE MATERIALLY DIFFERENT FROM THE RESULTS, PERFORMANCE OR OTHER EXPECTATIONS EXPRESSED OR IMPLIED BY THESE FORWARD-LOOKING STATEMENTS. THESE FACTORS INCLUDE RESULTS OF CURRENT OR PENDING RESEARCH AND DEVELOPMENT ACTIVITIES, ACTIONS BY THE FDA AND OTHER REGULATORY AUTHORITIES, AND OTHER FACTORS DESCRIBED IN THE COMPANY'S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION SUCH AS OUR 10K, 10Q AND 8K REPORTS. # # #


